#written-description

#written-description

Regents of the University of California ("Regents") and Broad Institute were engaged in a patent interference proceeding involving the adaptation of CRISPR systems to edit eukaryotic DNA. Both parties were engaged in extensive testing related to editing eukaryotic DNA during the time of the invention, and both filed multiple patent applications that became the subjects of the patent interference proceedings.

MSN Pharmaceuticals, Inc. subsequently filed a petition for certiorari to the Supreme Court in August of this year, arguing that there is "doctrinal chaos" surrounding the topic of after-arising technology in the context of patent infringement suits. While some Federal Circuit decisions have held "that when a patentee secures a claim construction that ensnares, as infringing, an accused device that features after-arising technology, the patentee risks invalidating its own patent on written-description and enablement grounds,"